S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
NASDAQ:IDXX

IDEXX Laboratories Stock Forecast, Price & News

$679.64
-2.94 (-0.43 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$671.34
$684.21
50-Day Range
$655.05
$705.76
52-Week Range
$364.58
$706.95
Volume196,475 shs
Average Volume408,796 shs
Market Capitalization$57.82 billion
P/E Ratio81.01
Dividend YieldN/A
Beta0.92
30 days | 90 days | 365 days | Advanced Chart
Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.


IDEXX Laboratories logo

About IDEXX Laboratories

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services, which are used to manage the health status of livestock and poultry, to improve producer, and to ensure the quality and safety of milk and food. The Other operating segment combines and presents products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.00 out of 5 stars

Medical Sector

574th out of 1,351 stocks

Diagnostic Substances Industry

6th out of 25 stocks

Analyst Opinion: 1.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

Is IDEXX Laboratories a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDEXX Laboratories stock.
View analyst ratings for IDEXX Laboratories
or view top-rated stocks.

What stocks does MarketBeat like better than IDEXX Laboratories?

Wall Street analysts have given IDEXX Laboratories a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IDEXX Laboratories wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting IDEXX Laboratories?

IDEXX Laboratories saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,050,000 shares, an increase of 23.2% from the August 15th total of 852,500 shares. Based on an average daily volume of 360,300 shares, the short-interest ratio is currently 2.9 days. Approximately 1.3% of the company's shares are short sold.
View IDEXX Laboratories' Short Interest
.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for IDEXX Laboratories
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its earnings results on Friday, July, 30th. The company reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.01 by $0.33. The business had revenue of $826.14 million for the quarter, compared to analyst estimates of $794.64 million. IDEXX Laboratories had a net margin of 23.89% and a trailing twelve-month return on equity of 115.28%. IDEXX Laboratories's revenue for the quarter was up 29.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.72 EPS.
View IDEXX Laboratories' earnings history
.

How has IDEXX Laboratories' stock price been impacted by Coronavirus (COVID-19)?

IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IDXX shares have increased by 176.7% and is now trading at $679.64.
View which stocks have been most impacted by COVID-19
.

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories announced that its Board of Directors has authorized a share buyback program on Wednesday, February 12th 2020, which allows the company to buyback 5,000,000 outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company's management believes its shares are undervalued.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories updated its FY 2021 earnings guidance on Friday, August, 6th. The company provided earnings per share guidance of $8.200-$8.360 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.100. The company issued revenue guidance of $3.17 billion-$3.21 billion, compared to the consensus revenue estimate of $3.14 billion.

What price target have analysts set for IDXX?

5 brokerages have issued twelve-month price targets for IDEXX Laboratories' stock. Their forecasts range from $570.00 to $770.00. On average, they anticipate IDEXX Laboratories' share price to reach $675.00 in the next year. This suggests that the stock has a possible downside of 0.7%.
View analysts' price targets for IDEXX Laboratories
or view top-rated stocks among Wall Street analysts.

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the following people:
  • Jonathan J. Mazelsky, President, Chief Executive Officer & Director
  • John Hart, Senior Vice President-Worldwide Operations
  • Brian Patrick McKeon, Chief Financial Officer, Treasurer & Executive VP
  • Jeffrey Thomas, Chief Technology Officer & Senior VP
  • Ken Grady, Chief Information Officer & Senior VP

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories CEO Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among IDEXX Laboratories' employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Square (SQ), The Walt Disney (DIS) and Shopify (SHOP).

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.66%), BlackRock Inc. (9.73%), State Street Corp (4.27%), Bamco Inc. NY (3.17%), Geode Capital Management LLC (2.01%) and Blair William & Co. IL (1.59%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends for IDEXX Laboratories
.

Which institutional investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Bamco Inc. NY, Marshall Wace North America L.P., Alliancebernstein L.P., JPMorgan Chase & Co., Nuveen Asset Management LLC, Vanguard Group Inc., and Westfield Capital Management Co. LP. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson, and Sophie V Vandebroek.
View insider buying and selling activity for IDEXX Laboratories
or view top insider-selling stocks.

Which institutional investors are buying IDEXX Laboratories stock?

IDXX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Amundi, State Street Corp, Capital International Investors, Bank of New York Mellon Corp, Neuberger Berman Group LLC, Franklin Resources Inc., and Geode Capital Management LLC.
View insider buying and selling activity for IDEXX Laboratories
or or view top insider-buying stocks.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $679.64.

How much money does IDEXX Laboratories make?

IDEXX Laboratories has a market capitalization of $57.82 billion and generates $2.71 billion in revenue each year. The company earns $581.78 million in net income (profit) each year or $6.71 on an earnings per share basis.

How many employees does IDEXX Laboratories have?

IDEXX Laboratories employs 9,300 workers across the globe.

When was IDEXX Laboratories founded?

IDEXX Laboratories was founded in 1983.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is www.idexx.com.

Where are IDEXX Laboratories' headquarters?

IDEXX Laboratories is headquartered at ONE IDEXX DRIVE, WESTBROOK ME, 04092.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at (207) 556-0300 or via email at [email protected].


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.